SCYX · SCYNEXIS, Inc.

SCYNEXIS completed its pivot from commercial revenue to a pure development-stage biopharma in Q1 2026, reporting $0 revenue versus $257K in the prior year. This -100% decline stems from the end of legacy product sales, allowing full resource allocation to clinical programs in antifungals and rare diseases like ADPKD. Investors should view this as a deliberate strategic shift, eliminating topline volatility while concentrating on high-potential pipeline milestones, though it eliminates near-term cash inflows.

Operating income deteriorated -96.7% to -$16.9M from -$8.6M, reflecting heightened R&D investments without revenue to absorb costs. This widening gap underscores the capital-intensive nature of advancing clinical candidates, where expenses accelerate ahead of potential partnerships or regulatory progress. Net income followed suit, plunging -295.1% to -$21.3M from -$5.4M, with diluted EPS at -$0.42 versus -$0.11. These metrics highlight the per-share burden of development-stage economics, where losses expand as programs mature toward value-inflecting data readouts.

Looking forward, SCYNEXIS plans a Phase 2 proof-of-concept study in ADPKD patients starting Q4 2026, with early efficacy data expected in the second half of 2027. This catalyst anchors the strategy, targeting a rare disease with significant unmet need. Management emphasizes pursuing non-dilutive funding to extend runway, aligning with clean inventory terms that exclude third-party claims or consignment risks. However, inherent uncertainties in regulatory approvals and development costs remain, as noted in disclosures. Success in ADPKD could validate the R&D pivot, potentially attracting partnerships, but execution across clinical timelines will determine if the revenue transition yields long-term value creation.